Skip to main content
. 2022 Apr 22;17(4):e0266707. doi: 10.1371/journal.pone.0266707

Table 3. Adverse effects of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil vs systemic gemcitabine-cisplatin combination therapy.

Adverse effects HAIC-GEM-FP (n = 18) GC (n = 24)
Any grade Grade 3 or 4 Any grade Grade 3 or 4 P
Leukopenia 2 (11.1) 1 (5.6) 11 (45.8) 3 (12.5) 0.049
Anemia 12 (66.7) 6 (33.3) 19 (79.2) 6 (25) 0.396
Thrombocytopenia 5 (27.8) 4 (22.2) 11 (45.8) 6 (25) 0.368
Hyperbilirubinemia 4 (22.2) 1 (5.6) 2 (8.3) 2 (8.3) 0.114
AST/ALT level elevation 4 (22.2) 0 (0) 4 (16.7) 0 (0) 0.650
Fever 4 (22.2) 0 (0) 3 (12.5) 0 (0) 0.403
General fatigue 3 (16.6) 0 (0) 2 (8.3) 0 (0) 0.409
Nausea/vomiting 1 (5.6) 0 (0) 2 (8.3) 0 (0) 0.729
Gastric ulcer 1 (5.6) 0 (0) 0 (0) 0 (0) 0.243
Artery occlusion 1 (5.6) 0 (0) - 0.243

Data are expressed as n (%)

AST, alanine aminotransferase; ALT, aspartate transaminase; GC, gemcitabine plus cisplatin combination therapy